Market size of iCo-019 (Oral Amp B) - Billions!!!!Quote from ICO NR in the past:


“Given our significant progress in contract manufacturing and pre-clinical development we have a highly differentiated Oral Amp B lead candidate rapidly making its way into the clinic," stated Andrew Rae, President and CEO. "Assuming clinical data reflects meaningful pre-clinical outcomes we believe we may address anti-fungal markets in excess of a billion dollars with an asset that makes administration far more accessible to a broad population."

Important info from the link given in the NR:


Highlights 


- The global market for antifungal drugs was valued at $13.1 billion in 2016. The market should reach $16.1 billion by 2021, growing at a compound annual growth rate (CAGR) of 4.2% from 2016 to 2021.
- The global market for prescription antifungal drugs was valued at $7.0 billion in 2016. The market should reach $8.3 billion by 2021, growing at a CAGR of 3.5% from 2016 to 2021.
- The global market for over the counter (OTC) antifungal drugs was valued at $6.1 billion in 2016. The market should reach $7.8 billion by 2021, growing at a CAGR of 5.0% from 2016 to 2021.
https://www.reportbuyer.com/product/2212016/antifungal-drugs-technologies-and-global-markets.html

iCo Therapeutics Inc  SMB: = ICO (Canada) ; ICOTF (USA)

ICO TOP PERFORMER on Venture Exchange 

84.4 mil. FD diluted shares

Recently ICO has traded some 150 million shares turning over their fully diluted share count more than Twice between June 20 to June 29 2018

ORAL B  Patient Results were release June 27 - Fantastic News as below:
..................................................................................................................................
ICO THERAPEUTICS ANNOUNCES POSITIVE CLINICAL OUTCOME  PRIMARY ENDPOINT MET IN PHASE 1 ORAL AMPHOTERICIN B STUDY

iCo Therapeutics Inc. and its subsidiary iCo Therapeutics Australia Pty. Ltd. have provided a positive primary end point in their phase 1 clinical study. The study met its primary end point of safety and tolerability of iCo-019 (oral amp B) following oral administration of single ascending doses (four dose levels) in healthy subjects. There were no serious adverse events (SAEs) and no drug-related adverse events (AEs) in either of the four study cohorts. All drug doses were well tolerated, including the highest dose of 800 milligrams, with no indication of kidney toxicity. "This is a very promising result for our future efficacy studies with oral amphotericin B," stated Dr. Peter Hnik, chief medical officer of iCo Therapeutics.

"We are pleased to report a positive primary end point related to our 32-subject phase 1 clinical study," stated Andrew Rae, president and chief executive officer of iCo Therapeutics. "No patients experienced drug-related adverse or serious adverse events in our phase 1 clinical study and we believe this allows us to claim leadership in the race towards developing an oral amphotericin B drug." Mr. Rae also stated, "iCo management waits with anticipation important and material pharmacokinetic data in the coming weeks
.......................................................................................................................................

Amphotericin B drug has been already in use for more than 50 years by such companies as Gilead Sciences (GILD) boasting a 92 billion dollar market cap
Amphotericin B generated a revenue 0f $621 million - fourth quarter of 2016

PROBLEM = administered via intravenous or injection in Patients in Hospital

ICO  ORAL B is the same drug (GILDamphotericin B ) but cusrrently being tested using their patented Oral Products. This is a FIRST and Exclusive methodology. This New Drug Form will streamline patient use with convenient at home personal medication being made possible. Millions of dollars in hospital costs and Doctor fees will be saved by using ORAL B in this new oral fashion rather than injection.

Question is, why would anyone continue using current methods of dosing?

ICO is about to KIDNAP a HUGE established market with this new research!

DoubleBank Believes the following Scheduled Clinical Trial Reports due this July will prove Explosive concerning the Stock Price of ICO We cannot predict how high ICO stock will travel long term. Although this is a forward looking statement we have every reason to believe stock holders will see nothing but positive results concerning medical trials that have just concluded in Australia on behalf of Ico Therapeutics. The next 2 soon to be seen milestones are a follows: 


1.   ORAL B  material pharmacokinetic data to be released in July

2. Bullous Pemphigoid Disease BP-01 material pharmacokinetic data to be released in July


DoubleBank rates ICO.v as a Strong Buy under 25 cents (CAD) and an extremely 

RARE OPPORTUNITY seated in a dull Market Environment - BUY ICO / ICOTF